Does intravenous methotrexate carried by lipid nanoemulsion improve LVEDV and other LVR parameters in patients with anterior ST-elevation myocardial infarction?
In patients with anterior STEMI, intravenous methotrexate carried by lipid nanoemulsion did not improve left ventricular remodeling but may reduce infarct size at 90 days.
In patients with STEMI, LDE-MTX appears to be safe but did not influence LVEDV and other LVR parameters, although it possibly reduced infarct size at 90 days. These hypothesis-generating results support further investigation of a novel nanomedicine approach to STEMI in larger trials.
Ferrari et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: